Cargando…

Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study

BACKGROUND: To date, few data on the safety profile of gadoterate meglumine in pediatric patients are available. PURPOSE: To assess the safety profile of gadoterate meglumine in routine practice, to detect any case of nephrogenic systemic fibrosis (NSF) suspicion and to collect efficacy data. MATERI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, De-Hua, Pracros, Jean-Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Contrast Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826856/ https://www.ncbi.nlm.nih.gov/pubmed/31027425 http://dx.doi.org/10.1177/0284185119840649

Ejemplares similares

Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)
por: Deray, Gilbert, et al.
Publicado: (2012)

Safety of gadobutrol: results of a non-interventional study of 3710 patients, including 404 children
por: Glutig, Katja, et al.
Publicado: (2018)

Respiratory anomalies associated with gadoxetate disodium and gadoterate meglumine: compressed sensing MRI revealing physiologic phenomena during the entire injection cycle
por: Glessgen, Carl Guillaume, et al.
Publicado: (2021)

Influence of aging and gadolinium exposure on T1, T2, and T2*-relaxation in healthy women with an increased risk of breast cancer with and without prior exposure to gadoterate meglumine at 3.0-T brain MR imaging
por: Krug, Kathrin Barbara, et al.
Publicado: (2021)

Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study
por: Soyer, Philippe, et al.
Publicado: (2016)

Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals
por: Young, Laura K., et al.
Publicado: (2018)

Ionic and non-ionic intravenous X-ray contrast media: antibacterial agents?
por: Mosler, Frank, et al.
Publicado: (2021)

Anaphylaxis to gadobutrol and gadoterate meglumine in a patient with low grade astrocytoma
por: Montalvo, Juan Manuel Escobar, et al.
Publicado: (2014)

Gadoterate meglumine decreases ADC values of breast lesions depending on the b value combination
por: Arponen, Otso, et al.
Publicado: (2018)

A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years
por: Scala, Mario, et al.
Publicado: (2018)

Gadolinium Retention and Clearance in the Diabetic Brain after Administrations of Gadodiamide, Gadopentetate Dimeglumine, and Gadoterate Meglumine in a Rat Model
por: Wang, Shu-ting, et al.
Publicado: (2019)

Lack of evidence of a relationship between magnetic resonance signal intensity changes in the globus pallidus and dentate nucleus, and repeated administrations of gadoterate meglumine in children
por: Lancelot, Eric, et al.
Publicado: (2017)

Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine, and Gadobutrol to rats
por: Bussi, Simona, et al.
Publicado: (2021)

Comprehensive Speciation Analysis of Residual Gadolinium in Deep Cerebellar Nuclei in Rats Repeatedly Administered With Gadoterate Meglumine or Gadodiamide
por: Strzeminska, Izabela, et al.
Publicado: (2022)

Intravenous contrast medium extravasation: systematic review and updated ESUR Contrast Media Safety Committee Guidelines
por: Roditi, Giles, et al.
Publicado: (2022)

Safety profile of gadoxetate disodium in elderly patients (≥65 years)
por: Endrikat, Jan, et al.
Publicado: (2017)

Safety of Gadoterate Meglumine (Gd-DOTA) as a Contrast Agent for Magnetic Resonance Imaging: Results of a Post-Marketing Surveillance Study in Japan
por: Ishiguchi, Tsuneo, et al.
Publicado: (2012)

Long-term safety of withholding standard prophylaxis in patients with moderate chronic kidney disease
por: Nijssen, E. C., et al.
Publicado: (2022)

Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients
por: Endrikat, Jan, et al.
Publicado: (2015)

The pharmacokinetic profile, tolerability and safety of the iodinated, non-ionic, dimeric contrast medium Iosimenol 340 injection in healthy human subjects
por: Meurer, Karoline, et al.
Publicado: (2015)

Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines
por: Stacul, Fulvio, et al.
Publicado: (2017)

Prospective multicenter assessment of patient preferences for properties of gadolinium-based contrast media and their potential socioeconomic impact in a screening breast MRI setting
por: Woolen, Sean A., et al.
Publicado: (2021)

Post-contrast acute kidney injury – Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines
por: van der Molen, Aart J., et al.
Publicado: (2018)

Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines
por: van der Molen, Aart J., et al.
Publicado: (2018)

Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial
por: Achenbach, Stephan, et al.
Publicado: (2016)

The fate of Gd and chelate following intravenous injection of gadodiamide in rats
por: Kindberg, Grete Mørk, et al.
Publicado: (2010)

MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine
por: Brismar, Torkel B., et al.
Publicado: (2011)

MR liver imaging with Gd-EOB-DTPA: a delay time of 10 minutes is sufficient for lesion characterisation
por: van Kessel, C. S., et al.
Publicado: (2012)

Biphasic contrast medium injection in cardiac CT: moderate versus high concentration contrast material at identical iodine flux and iodine dose
por: Rutten, Annemarieke, et al.
Publicado: (2010)

No increase in Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin excretion following intravenous contrast enhanced-CT
por: Kooiman, Judith, et al.
Publicado: (2015)

Intra-arterial and intravenous applications of Iosimenol 340 injection, a new non-ionic, dimeric, iso-osmolar radiographic contrast medium: phase 2 experience
por: Meurer, Karoline, et al.
Publicado: (2015)

ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents
por: Neri, E., et al.
Publicado: (2015)

What Evidence Is There That Gadobutrol Causes Increasing Signal Intensity within the Dentate Nucleus and Globus Pallidus on Unenhanced T1W MRI in Patients with RRMS?
por: Agris, Jacob, et al.
Publicado: (2015)

Contrast agent and radiation dose reduction in abdominal CT by a combination of low tube voltage and advanced image reconstruction algorithms
por: Buls, Nico, et al.
Publicado: (2014)

At Home—Somewhere in France
Publicado: (1919)

Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue
por: Jost, Gregor, et al.
Publicado: (2016)

Feasibility and accuracy of dual-layer spectral detector computed tomography for quantification of gadolinium: a phantom study
por: van Hamersvelt, Robbert W., et al.
Publicado: (2017)

Reduction of respiratory motion artifacts in gadoxetate-enhanced MR with a deep learning–based filter using convolutional neural network
por: Kromrey, M.-L., et al.
Publicado: (2020)

Impact on clinical practice of updated guidelines on iodinated contrast material: CINART
por: Nijssen, E. C., et al.
Publicado: (2020)

USPIO-enhanced MRI of pelvic lymph nodes at 7-T: preliminary experience
por: Philips, Bart W. J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hrbure597of6r4ns694mifvj3h